公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2023-056 九芝堂股份有限公司 关于持股 5%以上股东权益变动达到 1%的公告 | 1.基本情况 | | | | | --- | --- | --- | --- | | 信息披露义务人 | 黑龙江辰能工大创业投资有限公司 | | | | 住所 | 黑龙江省哈尔滨市南岗区玉山路 | 22 号 | | | 权益变动时间 | 2023 年 6 月 13 日——2023 | 年 10 月 26 日 | | | 股票简称 | 九芝堂 | 股票代码 | 000989 | | 变动类型 （可多选） | 增加□ 减少√ | 一致行动人 | 有□ 无√ | | 是否为第一大股东或实际控制人 | | | 是□ 否√ | | 2.本次权益变动情况 | | | | | 股份种类（A 股、 | 减持股数（万股） | 减持比例 | 减持日期 | | B 股等） | | | | | A 股 | 855.9400 | 2023 年 6 1% | 月 13 日——2023 年 10 月 26 日 | | 合 计 | 855.9400 | 1% | / | | 本次权益变动方 ...

Group 1: Event Details - The event is titled "2023 Hunan Listed Companies Investor Online Collective Reception Day" [2] - It will be held on November 2, 2023, from 15:30 to 17:00 [2] - Investors can participate via the "Panjing Roadshow" website, WeChat public account, or the Panjing Roadshow APP [2] Group 2: Company Commitment - The company and its board guarantee the authenticity, accuracy, and completeness of the announcement [2] - They accept joint liability for any false records, misleading statements, or significant omissions [2] Group 3: Interaction Focus - Company executives will communicate with investors regarding development strategies and operational status [2] - The event aims to enhance interaction and communication with investors [2]

Financial Performance - The company's operating revenue for the current reporting period is ¥551,322,356.98, a decrease of 3.99% compared to the same period last year[13]. - Net profit attributable to shareholders for the current reporting period is ¥43,908,213.25, an increase of 91.92% year-on-year[13]. - Net profit attributable to shareholders after deducting non-recurring gains and losses is ¥34,247,726.32, up 97.93% compared to the same period last year[13]. - The net profit for the third quarter is 287,515,147.59 yuan, a decrease from 388,794,815.90 yuan in the same period last year, representing a decline of approximately 26%[29]. - The total profit for the quarter is 346,940,382.42 yuan, down from 503,003,968.20 yuan year-on-year, indicating a decrease of about 31%[29]. - The company’s operating profit for the quarter is 346,347,507.16 yuan, down from 500,149,564.49 yuan year-on-year, reflecting a decrease of approximately 31%[29]. - The total comprehensive income attributable to the parent company for the current period is CNY 302,296,687.66, compared to CNY 373,677,043.63 in the previous period, reflecting a decrease of approximately 19.1%[32]. - Basic and diluted earnings per share for the current period are both CNY 0.3373, down from CNY 0.4572 in the previous period, indicating a decline of about 26.2%[32]. Assets and Liabilities - Total assets increased to ¥5,398,434,079.72 from ¥5,239,728,801.58, representing a growth of approximately 3.03%[1]. - Current liabilities rose to ¥1,366,623,705.14 from ¥1,159,506,104.85, an increase of about 17.88%[1]. - Non-current liabilities decreased to ¥91,070,406.22 from ¥98,955,228.70, a decline of approximately 8.93%[1]. - Total liabilities increased to ¥1,457,694,111.36 from ¥1,258,461,333.55, a rise of about 15.83%[1]. - Total equity attributable to shareholders decreased to ¥3,945,310,836.44 from ¥3,984,827,136.94, a reduction of about 1.00%[5]. - The total current assets increased to ¥2,972,101,611.61 from ¥2,797,935,355.28, reflecting a growth of about 6.19%[6]. Cash Flow - The net cash flow from operating activities decreased by 87.94% year-on-year, amounting to ¥45,668,461.80[13]. - The net cash flow from operating activities for the current period is CNY 45,668,461.80, compared to CNY 378,827,633.83 in the previous period, indicating a significant decline[33]. - The net cash flow from investing activities for the current period is -CNY 612,418,606.77, slightly worse than -CNY 598,740,917.76 in the previous period[35]. - The net cash flow from financing activities for the current period is -CNY 128,660,899.54, compared to -CNY 361,063,945.95 in the previous period, showing an improvement[35]. - The total cash and cash equivalents at the end of the period is CNY 393,934,400.07, down from CNY 227,103,425.45 in the previous period[35]. - Cash and cash equivalents decreased to ¥393,934,400.07 from ¥1,089,345,444.58, a decline of approximately 63.8%[6]. Accounts Receivable and Inventory - Accounts receivable increased to ¥649,308,222.42 from ¥291,350,016.43, representing a growth of about 123.5%[6]. - Inventory increased to ¥788,287,399.63 from ¥749,171,033.03, an increase of approximately 5.2%[6]. - The company reported a significant increase in accounts receivable by 122.86%, reaching ¥64,930.82 million[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 53,717, with the top 10 shareholders holding a combined 56.05% of shares[21]. - Li Zhenguo holds 25.17% of shares, while Heilongjiang Cheneng Gongda Venture Capital Co., Ltd. holds 18.79%[21]. - The report indicates that there are no related party relationships among the top 10 shareholders, and they are not acting in concert[21]. Research and Development - The company’s subsidiary, Mudanjiang Youbo Pharmaceutical Co., Ltd., received approval for clinical trials of a new drug, YB211, from the National Medical Products Administration[24]. - Research and development expenses increased slightly to CNY 91,241,164.16 from CNY 88,935,071.45, reflecting a growth of about 2.5%[36]. Operating Costs - Total operating costs for the current period are CNY 2,066,143,905.54, down from CNY 2,217,629,799.25, representing a reduction of about 6.8%[36]. - The company reported a decrease in sales expenses to CNY 869,241,636.60 from CNY 888,599,556.72, a reduction of approximately 2.9%[36].

关于控股股东部分股份质押及解除质押的公告 公告文件 证券代码：000989 证券简称： 九芝堂 公告编号：2023-053 九芝堂股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 九芝堂股份有限公司（以下简称"公司"）近日接到公司控股股东李振国先 生函告，获悉上述股东所持公司部分股份被质押及解质押，具体事项如下： | 股东名称 | 是否为控股股东或第 | 本次解除质 | 占其所持 | 占公司总 | | | 质权人/ | | --- | --- | --- | --- | --- | --- | --- | --- | | | 一大股东及其一致行 动人 | 押股份数量 | 股份比例 | 股本比例 | 起始日 | 解除日期 | 申请人等 | | 李振国 | 控股股东 | 22,044,090 | 10.23% | 2.58% | 2023/1/19 | 2023/9/25 | 华创证券 | | | | 3,355,110 | 1.56% | 0.39% | 2023/4/4 | 2023/9/25 | 华创证券 | | | | 5,070,140 | ...

公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2023-052 九芝堂股份有限公司 关于全资子公司研发新药获得临床试验批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 九芝堂股份有限公司(以下简称"公司"或"本公司")全资子公司牡丹江 友搏药业有限责任公司(以下简称"友搏药业")研发的新药注射用咔喏霉素（即 YB211 项目）近日收到国家药品监督管理局核准签发的《药物临床试验批准通知 书》，现将有关情况公告如下： 1、临床试验批准通知书的主要内容 药品名称：注射用咔喏霉素 受理号：CXHL2300747 申请人：牡丹江友搏药业有限责任公司 申请适应症：对本品敏感的革兰氏阳性病原菌所致的复杂性皮肤及软组织感 染（cSSTI）。 审批结论：同意本品开展临床试验。 2、该药品的其他相关情况 YB211 项目是具有全新化学结构的环脂肽类 1 类化药新药，其化合物、制备 方法等核心技术均已获得国际和国内发明专利授权与全球独家许可，其研发旨在 提高环脂肽类抗菌药物的安全性与有效性，为临床提供一种新的选择。本品在中 国首次申报临床试验，为评价中国健 ...

Financial Performance - In the first half of 2023, the company achieved operating revenue of 1.819 billion yuan, a decrease of 3.72% compared to the same period last year [2] - Net profit attributable to shareholders was 245 million yuan, down 33.55% year-on-year, primarily due to the non-inclusion of revenue from the divested subsidiary, Jiuzhitang Medicine [2] - The net profit excluding non-recurring gains and losses was 236 million yuan, an increase of 77.40% year-on-year, driven by increased product sales and improved gross margin [2] Impact of Raw Material Prices - The rise in Chinese medicinal material prices has affected the company's gross margin [3] - The company monitors key raw materials and implements strategic reserves and inventory management to mitigate price fluctuations [3] - Continuous improvement in production technology and optimization of production processes are being pursued to control production costs [3] Product Characteristics and Market Dynamics - The pharmaceutical industry is characterized by inelastic demand, making it less susceptible to seasonal fluctuations [3] - Certain products, such as blood tonics, see increased demand in autumn and winter [3] Research and Development Focus - The company is focusing on stem cell therapy, innovative drugs, and the secondary development of existing products [3] - Key projects include clinical trials for ischemic stroke treatment and the development of traditional Chinese medicine formulations [3] OTC Market Strategy - The company is expanding its OTC product lines, particularly in health supplements and chronic disease management [4] - Marketing efforts and brand influence are driving channel expansion and market penetration [4] Subsidiary Sales and Integration - Subsidiaries are focusing on specific products, with a completed sales team structure for integrated production and sales [4] - Key products include Xuexitong injection and various traditional Chinese medicine formulations [4] Pricing Strategy - The company plans to adjust pricing strategies based on cost changes, policy conditions, target demographics, and market environment [4]

Shareholder Meetings - The company held its first extraordinary general meeting of shareholders in 2023 with a participation ratio of 46.46% on January 10, 2023[2]. - The annual general meeting of shareholders in 2022 had a participation ratio of 55.44% on May 24, 2023[2]. Environmental Compliance - The company has implemented strict environmental monitoring and published all self-monitoring data as required in the first half of 2023[6]. - The company emphasizes environmental protection and has achieved compliance with national standards for waste disposal, wastewater treatment, and emissions control[8]. - The company has implemented measures to reduce carbon emissions, although specific results were not disclosed[7]. - The company has maintained stable pollutant discharge levels across its three production sites, with total emissions below the approved limits[100]. - The company has plans for future expansion and investment in wastewater treatment technologies to enhance compliance and sustainability[135]. - The company is actively monitoring and managing wastewater discharge to ensure compliance with environmental regulations[135]. - The company has established emergency response plans for environmental incidents, with registrations completed in 2021 and 2022[137]. - The company has maintained compliance with environmental discharge standards, with specific pollutant levels reported[112][115]. Corporate Governance - The company has established a robust corporate governance system to protect creditor rights and ensure financial stability[8]. - The company reported a commitment to avoid competition with its controlling shareholder, Li Zhenguo, ensuring no direct or indirect involvement in competing businesses during his tenure as a controlling shareholder[28]. - Li Zhenguo and associated parties committed to reducing and regulating related party transactions to protect the company's interests, ensuring fair and lawful agreements are made if necessary[28]. - The company confirmed that there were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[32]. - The company has maintained its independence in operations, finance, and governance, ensuring no interference from controlling shareholders[28]. - There were no significant litigation or arbitration matters affecting the company during the reporting period[38]. - The company has not engaged in any violations regarding external guarantees during the reporting period[33]. - There were no significant related party transactions reported, ensuring transparency and compliance with regulations[40]. - The company has not undergone any bankruptcy restructuring during the reporting period, indicating financial stability[37]. - The company has maintained a clean integrity status with no unfulfilled court judgments or significant debts due during the reporting period[39]. Financial Performance - The company's operating revenue for the reporting period was ¥1,818,909,467.04, a decrease of 3.72% compared to ¥1,889,171,555.86 in the same period last year[55]. - The net profit attributable to shareholders was ¥244,827,549.04, down 33.55% from ¥368,443,161.49 in the previous year, primarily due to investment income from the 51% equity transfer of Jiuzhitang Pharmaceutical in the previous year[55]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 77.40% to ¥236,067,910.38, driven by increased product sales and improved gross margin[55]. - The net cash flow from operating activities decreased by 50.73% to ¥138,156,212.78, mainly due to an increase in accounts receivable and the exclusion of Jiuzhitang Pharmaceutical from the consolidated financial statements[55]. - Total assets at the end of the reporting period were ¥5,488,411,303.99, an increase of 4.77% from ¥5,238,415,577.39 at the end of the previous year[55]. - The company's weighted average return on equity was 6.04%, down 2.83% from 8.87% in the previous year[55]. - The company reported a total of ¥1,048,414,502.00 in undistributed profits, down from ¥1,145,963,757.76, a decrease of about 8.5%[185]. - Total operating revenue for the first half of 2023 was CNY 1,818,909,467.04, a decrease of 3.8% compared to CNY 1,889,171,555.86 in the same period of 2022[194]. - Total operating costs decreased to CNY 1,543,377,122.69 from CNY 1,684,136,256.53, reflecting a reduction of approximately 8.4%[194]. - Net profit for the first half of 2023 was CNY 243,903,752.14, down 33.5% from CNY 366,909,887.08 in the first half of 2022[197]. - Earnings per share (EPS) for the first half of 2023 was CNY 0.28603, compared to CNY 0.43045 in the same period of 2022, indicating a decline of 33.5%[197]. - The company's total liabilities increased to CNY 1,662,466,711.12 from CNY 1,367,891,283.27, representing a growth of approximately 21.5%[194]. - Total equity rose to CNY 9,146,012,886.47 from CNY 9,067,837,165.09, an increase of about 0.9%[194]. - Research and development expenses for the first half of 2023 were CNY 60,904,100.05, up from CNY 51,465,136.34, reflecting a growth of approximately 18.9%[194]. Product Development and Market Position - The company is positioned to benefit from the growing demand for traditional Chinese medicine, particularly in the context of an aging population and increasing chronic disease prevalence[66]. - The State Administration for Market Regulation has introduced new regulations to strengthen the management of traditional Chinese medicine, which is expected to create new opportunities for research and development in this area[67]. - The company anticipates that the implementation of the "14th Five-Year Plan" will enhance the development of traditional Chinese medicine services and innovation capabilities[67]. - The pharmaceutical industry is facing challenges such as price pressures and increased competition, but it is also expected to achieve high-quality development driven by innovation and policy support[66]. - The company has developed a series of blood-nourishing products centered around donkey-hide gelatin, with the "Donkey-hide Gelatin Blood Nourishing Granules" ranking among the top in the national retail market for blood-nourishing products[71]. - The company has a total of 211 products included in the 2022 National Medical Insurance Catalog, with 137 in Category A and 74 in Category B, including 9 exclusive varieties[88]. - The company has established a modern large-scale pharmaceutical enterprise with 19 subsidiaries, integrating research, production, sales, and health management[68]. - The company has 327 national drug registration approvals, including 35 exclusive varieties, covering various fields such as cardiovascular, kidney tonics, and women's and children's health[88]. - The company has developed innovative businesses in stem cells and health services, expanding its product offerings beyond traditional Chinese medicine[68]. - The company has a strong brand advantage and product reputation in the OTC traditional specialty products across various medical fields[71]. - The company achieved steady growth in sales of its main products, including Shu Xue Tong injection, with significant performance improvements in the first half of 2023 compared to the same period last year[149]. - The company is advancing multiple projects, including re-evaluation of existing products and innovation in drug development, with key products undergoing pharmacological and clinical effectiveness studies[150]. - The YB209 project has officially started clinical trials, and the YB211 project has received formal acceptance for clinical trial application from the National Medical Products Administration[150]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 51,855, with a total shareholding of 215,398,371 shares, representing 25.17%[145]. - The company’s management has locked shares, with a total of 197,951,459 limited sale shares at the beginning of the period, and 31,883,925 shares released during the period[143]. - The company’s stockholder, Li Zhenguo, holds 25.17% of the shares, with 165,711,278 shares under limited sale conditions[145]. - The company reported a decrease in limited sale shares from 197,951,459 (23.13%) to 166,067,534 (19.40%) after a reduction of 31,883,925 shares[140]. - The total number of shares increased from 855,942,012 to 855,942,012, with no change in total shares[140]. - The company has not reported any changes in the status of pledged, marked, or frozen shares[145]. Operational Efficiency - The company has optimized its management structure to enhance operational efficiency and has implemented a budget management system to improve service efficiency[155]. - The company is committed to optimizing its organizational structure and enhancing production efficiency to strengthen its core competitiveness[98]. - The procurement strategy includes competitive bidding and direct sourcing to reduce costs and manage supply effectively[91]. - The sales model combines self-operated and agency sales, expanding both traditional and online sales channels[92]. - The company has implemented a production model that emphasizes quality, safety, and environmental protection, adhering to national GMP standards[90]. Awards and Recognition - The company has received multiple awards, including being ranked among the "Top 100 Chinese Traditional Medicine Enterprises" and recognized for its high-quality development in the pharmaceutical industry[157]. - The company reported a brand value of 10.803 billion RMB, ranking in the top 10 of the "Chinese Time-honored Brand Value List" with a brand strength score of 871[159]. - The company received multiple awards for quality and brand recognition, including being named a "Leading Brand in the Pharmaceutical Industry" by the China Quality Inspection Association[158].

Group 1: Company Overview - Jiuzhitang Co., Ltd. was established in 1999 and listed on the Shenzhen Stock Exchange in 2000, evolving into a large modern pharmaceutical enterprise with 19 subsidiaries [1] - The company holds 309 national drug registration certificates, including 35 exclusive varieties, covering various fields such as cardiovascular, kidney, and pediatric health [1] Group 2: Financial Performance - In 2022, the company achieved a revenue of CNY 3.033 billion, a decrease of 19.84% year-on-year, primarily due to the sale of 51% equity in its subsidiary Jiuzhitang Medicine, which affected the consolidated financial statements by CNY 5.91 billion [2] - The net profit attributable to shareholders was CNY 359 million, an increase of 32.75% year-on-year, mainly due to investment income from the equity transfer, amounting to CNY 211 million [2] - In Q1 2023, the company reported a revenue of CNY 1.089 billion, down 8.97% year-on-year, while the net profit attributable to shareholders was CNY 161 million, up 30.72% [2] Group 3: Strategic Initiatives - The company aims to provide comprehensive health management from prevention to treatment, guided by the "14th Five-Year Plan" for high-quality development [1][2] - The company is enhancing its marketing strategies and expanding sales channels for its products, including the Xuexue Tong injection [3] Group 4: Shareholder Information - The second-largest shareholder announced a reduction of up to 17,118,840 shares, not exceeding 2% of the total share capital, due to personal funding needs [4] - The controlling shareholder is actively reducing the equity pledge ratio through share reductions and transfers to optimize the shareholder structure [4]

证券代码：000989 证券简称：九芝堂 2 | 经营 | 9 | 公司安宫牛黄丸有提价计划 | 针对具体产品，公司综合考虑成本变动情况、政策情况、产品 | | --- | --- | --- | --- | | | | | 受众群体以及市场环境等，兼顾消费者接受度、产品可持续发 | | | | 吗 | 展与公司盈利水平等，制定具体价格计划。如有相关重要事项 | | | | | 触及信息披露标准，公司将及时进行披露。 | | 经营 | 10 | 公司产品在海外市场销售如 | 公司产品在海外市场目前处于产品推广与品牌建设阶段，销售 | | | | 何？如巴西等 | 量较小。 | | | | 建议收购打造双天然安宫牛 黄、八宝丹、紫金锭、震灵丹、 | | | | | 金牛眼药之类的产品，目前公 | | | 经营 | 11 | | 投资者您好。感谢您对公司的关注和建议。 | | | | 司所谓的第一梯队产品其实 | | | | | 在名气上无法和其他的公司 | | | | | 主打产品媲美。 | | | | | 建议继续收购各类经典丸药 | | | | | 批号，打造九芝堂的经典名方 | | | 经营 | 12 | ...

临时公告 证券代码：000989 证券简称：九芝堂 公告编号：2023-037 九芝堂股份有限公司 关于召开 2022 年度业绩说明会并征集问题的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 九芝堂股份有限公司（以下简称"公司"）2022 年年度报告已于 2023 年 4 月 29 日披露。为使广大投资者更加全面、深入地了解公司情况，公司将于 2023 年 5 月 23 日（星期二）以网络方式举办 2022 年度业绩说明会，具体如下： 一、业绩说明会相关安排 1、时间：2023 年 5 月 23 日（星期二）下午 15:00-17:00。 2、召开方式：本次业绩说明会将采用网络方式召开，公司与投资者通过线 上文字方式进行互动问答。 3、参与方式：投资者可通过全景网 "投资者关系互动平台" （https://ir.p5w.net） 网络线上参与，并实时参与互动问答。 4、公司出席人员：董事长李振国先生，董事、总经理徐向平先生，独立董 事孙健先生，财务总监张梁彬先生，董事会秘书韩辰骁先生。 二、投资者问题征集及方式 公司现向投资者提前征集公司 2022 年 ...